GlassScriptPhysician profile
Bethany A Cummings
NPI 1205356870
$2,407.51
in general payments reported to CMS, 2019-2025
21 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.78 · 2022: $215 · 2023: $598 · 2024: $482 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.89 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.01 | 2021-2025 | |
| Amgen INC. | $301.18 | 2023-2025 | Prolia, Repatha, Repatha |
| Novo Nordisk INC | $222.50 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $205.05 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.58 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $189.11 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $147.85 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $101.93 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $91.53 | 2022-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $79.15 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $67.10 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $59.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $54.15 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $49.17 | 2024-2025 | Voquezna |
| Lundbeck LLC | $42.91 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.42 | 2024-2025 | Ofev, Jardiance |
| Corcept Therapeutics | $31.24 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $28.69 | 2025 | Auvelity |
| Boston Scientific Corporation | $20.75 | 2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $16.47 | 2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.